Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Sun Pharmaceutical Industries has elevated Aalok Shanghvi, son of the drugmaker’s founder promoter Dilip Shanghvi, as the Chief Operating Officer. Aalok (40 years), continues as Whole-time ...

Dividend stocks today: Shares of six companies, namely Sun Pharmaceutical Industries, Container Corporation of India, IRB Infrastructure Developers, Triveni Turbine, Sharda Cropchem and India ...

Sun Pharma delivered a strong Q3 performance, surpassing Street expectations. However, concerns over the uncertain launch timeline of its hair loss drug Leqselvi and a cut in R&D spending have led ...

The launch timeline of Sun Pharma's specialty drug Leqselvi (deuruxolitinib) continues to be stuck in a limbo even after two quarters since it got embroiled in a patent dispute. The drug ...

Sun Pharma Q3 Results: Sun Pharmaceutical Industries on Friday said its consolidated net profit increased 15 per cent on-year to Rs 2,903 crore in the December quarter, riding on robust sales across ...

Sun Pharmaceutical Industries Ltd is set to release its Q3 earnings for the quarter ending December 31, 2024, on Friday, January 31. The board will review and decide on the declaration of an ...

Drugmaker Sun Pharmaceutical Industries has entered into a definitive agreement to acquire 100% stake in Antibe Therapeutics Inc., an Ontario, Canada incorporated clinical-stage biotechnological ...

Sun Pharmaceutical Industries Ltd. 524715 shares inched down 0.77% to 1,753.40 Indian rupees Wednesday, on what proved to be an all-around poor trading session for the stock market, with the BSE ...

HYDERABAD/BENGALURU Jan 31 (Reuters) - Sun Pharmaceutical (SUN.NS), opens new tab, India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided by strong ...

A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs for pain and inflammation that fell into receivership last year.